VA-REGULA
25.7.2024 08:01:30 CEST | Business Wire | Press release
Regula, a global developer of forensic devices and identity verification solutions, prepared a dedicated package of expert articles focused on document verification, tailored to meet the needs of carriers, border verification authorities, the hospitality industry, and businesses during the 2024 Olympics. These resources aim to address the unique challenges posed by the influx of international visitors, ensuring seamless and secure experiences for all.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240724663488/en/
Effective Identity Verification for the Olympics 2024: how is it done? Regula's vision (Graphic: Regula)
France anticipates a significant boost in tourism and economic activity during the 2024 Olympics, with over 10 million visitors projected to generate an estimated €3 billion in revenue. This massive surge in visitors will not only increase the risk of fraud targeting consumers and businesses but also pose substantial challenges for security and access management. The influx of international guests underscores the critical need for advanced and comprehensive Identity Verification (IDV) systems.
Properly verifying and authorizing everyone at every stage of their Olympic journey is essential for maintaining security and ensuring smooth access to event venues and services.
1. Addressing Carrier Requirements for Advance Passenger Information
With recent EU regulations mandating the collection of advance passenger information, carriers face unprecedented challenges. Our topic, "How Carriers Can Tackle New Requirements for Gathering Advance Passenger Information," provides comprehensive insights and practical solutions to help carriers comply with these regulations efficiently. As the Olympics are hosted in France, this information is crucial for ensuring smooth travel experiences for millions of visitors.
2. Professional Border Verification Techniques
Border control is a critical component of international events. Our resources include:
- "How to Verify a Passport Like a Pro": A detailed guide on the best practices for passport verification.
- "How Regula Creates the Most Full and Detailed Document Reference System": An in-depth look at how Regula's advanced technology supports border control authorities with the most comprehensive document reference systems available. It contains templates of passports, ID cards, visas, banknotes, coins, driver’s licenses, and vehicle documents from all over the world.
- To gain a better understanding of the verification tools needed, from border controls to customer authorization by businesses, check the article “Regula ID Document Templates Database vs. Information Reference System”.
These topics are designed to empower border officials with the knowledge and tools needed to maintain security while facilitating the flow of visitors.
3. Transforming Travel & Hospitality with Data Entry Automation
In the hospitality sector, efficient check-ins are vital for a positive guest experience. At the same time, manual entry of ID details in hotels can often cause long lines, messes, and delays.
Our topic, "How Data Entry Automation Transforms Travel & Hospitality," highlights the latest innovations in reader technology and software. It provides examples of automated check-in processes and calls to action for hospitality businesses to leverage these advancements for a competitive edge.
4. Solving Business Challenges of Foreign Documents Verification
Businesses are facing an increase in the number of international customers, and the smart ones start adapting to the challenges of verifying foreign documents. Our article, "Foreign ID Document Verification for Businesses,” offers practical advice and solutions for businesses to navigate these complexities, ensuring they can confidently verify the identities of international customers.
To get access to all the expert articles in one place, visit the landing page “Securing the Olympics 2024”.
About Regula
Regula is a global developer of forensic devices and identity verification solutions. With our 30+ years of experience in forensic research and the largest library of document templates in the world, we create breakthrough technologies in document and biometric verification. Our hardware and software solutions allow over 1,000 organizations and 80 border control authorities globally to provide top-notch client service without compromising safety, security, or speed. Regula has been repeatedly named a Representative Vendor in the Gartner® Market Guide for Identity Verification.
Learn more at www.regulaforensics.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240724663488/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press release
Potential first-in-class GPC3 x 4-1BB bispecific achieves a 36% confirmed response rate at Phase 3 dose and favorable safety profile in heavily pretreated liver cancerBrain-penetrant PRMT5 inhibitor shows promising antitumor and CNS activity in the largest publicly shared MTAP-deficient datasetFirst clinical data of CEA-targeting ADC demonstrates encouraging and sustained responses in CEAhigh NSCLC BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to dise
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
